Bayer adjusted profit gains 15.8 percent on Monsanto, consumer health
Reuters
Published Feb 27, 2019 06:43
Bayer adjusted profit gains 15.8 percent on Monsanto, consumer health
FRANKFURT (Reuters) - Bayer's adjusted core earnings rose 15.8 percent in the fourth quarter, boosted by the addition of U.S. seeds maker Monsanto (NYSE:MON) and as its consumer healthcare business bounced back from earlier declines.
Fourth-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose to 2.07 billion euros (1.78 billion pounds), the maker of pharmaceuticals and farming pesticides said on Wednesday, beating the average analyst projection of 2.0 billion euros.
Previously announced write-downs on the value of consumer health brands and one-off charges from the closure of a German haemophilia drug plant led to a quarterly net loss of 3.9 billion euros.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.